Impact of the COVID-19 Pandemic on Drug-Resistant Tuberculosis in Europe: A Meta-Analysis of Epidemiological Trends
Pharmaceuticals · 12.10.2025 · 18 (10) · 1535
DOI: 10.3390/ph18101535 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 12.10.2025. Verfasst von Christina Zouganeli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, University of West Attica, 12243 Aigaleo, Greece. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: The COVID-19 pandemic has significantly intensified global concerns surrounding antimicrobial resistance (AMR), particularly in relation to tuberculosis (TB). In the European Union (EU), the reallocation of healthcare resources towards managing COVID-19 led to a de-prioritization of TB surveillance and control. This shift contributed to delays in TB diagnosis and treatment, creating conditions favorable for the emergence and spread of drug-resistant TB strains. This meta-analysis aims to assess epidemiological trends of drug-resistant TB across EU countries before, during, and after the pandemic and quantify the impact of COVID-19 on Mycobacterium tuberculosis resistance patterns.
Methods
Data were obtained from the European Centre for Disease Prevention and Control (ECDC) covering 2015 to 2022. Following the TB incidence, the multidrug-resistant TB (MDR-TB) and rifampicin-resistant/MDR-TB (RR/MDR-TB) cases, as well as treatment success rates over 12- and 24-month periods, were analyzed. The analysis included 31 EU countries across three-time frames: pre-pandemic (2015–2019), pandemic onset (2020), and post-pandemic transition (2020–2022).
Results
The pandemic was associated with a decrease in reported TB cases but a simultaneous increase in the proportion of MDR and RR/MDR cases. Treatment success rates showed a modest rise for 24-month regimens, while outcomes declined for 12-month therapies.
Conclusions
These findings underscore the pandemic’s disruptive impact on TB control and highlight the need for renewed investment in diagnostic capacity, treatment access, and antimicrobial stewardship, in order to reduce antimicrobial resistance occurrence. Continued monitoring beyond 2022 is essential to fully understand long-term effects and inform future public health strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Sciences, University of West Attica, 12243 Aigaleo, Greece.
- Immunology of Infection Group, Department of Microbiology, Hellenic Pasteur Institute, 11521 Athens, Greece.
- National Reference Laboratory for Bovine Tuberculosis, Directorate of Veterinary Centre of Athens, Ministry of Rural Development and Food, 15310 Athens, Greece.
- Department of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
ORCID-Profile: Dimitra K Toubanaki, Georgia Vrioni, Antonia Efstathiou
Zitieren
APA
Zouganeli, C., Toubanaki, D. K., Karaoulani, O., Vrioni, G., Karagouni, E., & Efstathiou, A. (2025). Impact of the COVID-19 Pandemic on Drug-Resistant Tuberculosis in Europe: A Meta-Analysis of Epidemiological Trends. Pharmaceuticals, 18(10), 1535. https://doi.org/10.3390/ph18101535
Vancouver
Zouganeli C, Toubanaki DK, Karaoulani O, Vrioni G, Karagouni E, Efstathiou A. Impact of the COVID-19 Pandemic on Drug-Resistant Tuberculosis in Europe: A Meta-Analysis of Epidemiological Trends. Pharmaceuticals. 2025;18(10):1535. doi:10.3390/ph18101535
BibTeX
@article{Zouganeli2025,
author = {Zouganeli, Christina and Toubanaki, Dimitra K and Karaoulani, Ourania and Vrioni, Georgia and Karagouni, Evdokia and Efstathiou, Antonia},
title = {Impact of the COVID-19 Pandemic on Drug-Resistant Tuberculosis in Europe: A Meta-Analysis of Epidemiological Trends},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {10},
pages = {1535},
doi = {10.3390/ph18101535}
}
EUVIMED